| Revenue growth | FY26: 37.1% YoY (₹2053.1cr); Q4FY26: 134.9% YoY (₹788.7cr). |
|---|---|
| Margins | EBITDA margin expanded to 29.4% in FY26 (up 650 bps). |
| Order book | Growth in new project orders for current and next FY. |
| Demand visibility | Strong visibility in short to medium term for commercial molecules. |
| Management confidence | High; citing good business visibility and strong note ending FY26. |
Growth
FY26 Revenue grew 37.1% to ₹2,053.1cr; PAT surged 40% to ₹363.1cr. Q4FY26 EBITDA margin reached 40.5%.
Outlook
Investing in Peptide manufacturing and a new R&D center; FY26 Capex outflow was ₹397cr.
Risks
Specialty segment remains subdued due to specific molecule performance; working capital and inventory fluctuations noted.
Earnings Call filed with NSE, NSE: NEULANDLAB. Summary written with AI assistance from the document.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹21,890.00
- Market cap
- ₹28,085 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 56.4×Sector 50.4×
- Promoter holding
- 32.62%-0.01% QoQ
- FII holding
- 21.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Production Started
Neuland commissioned its first commercial peptide manufacturing module with 7,000L reactor capacity. Module two expansion is underway to meet rising customer demand for peptide APIs.
- peptide manufacturing reactor capacity
- 7000 L
Neuland Laboratories Capacity Expansion: ₹126 Cr Investment
Neuland Laboratories' board approved ₹126 Crore capex to acquire 134 acres of land in Andhra Pradesh for future expansion. The company holds ROFR on additional land.
- Value
- ₹126.0 Cr
- land acquisition
- 134.0 acres
Neuland Laboratories Earnings Call Transcript: Key Takeaways
Q1FY27 was broadly in line with expectations, showing strong YoY revenue and profit growth. Management remains confident in achieving a 20% growth rate despite inherent quarterly volatility in the CMS business.
- Call
- Guides 20% growth
Neuland Laboratories Investor Presentation: Key Takeaways
Neuland reported Q1FY27 total income of ₹650.1 Cr (116.3% YoY growth) with an EBITDA margin of 35.5%. Growth is driven by the CMS business and commercial molecules.
Neuland Laboratories Q1 FY27 Results: Net Profit ₹147.7 Cr, Up 962.6% YoY
Neuland Laboratories Ltd reported revenue from operations of ₹641.6 Cr (+119.1% YoY) and net profit of ₹147.7 Cr (+962.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹147.7 Cr · +962.6% YoY
Neuland Laboratories Earnings Call: Key Takeaways
Neuland reported record performance for Q4FY26, driven by high-value CMS commercial projects and favorable exchange rates, achieving an exceptional 40.5% EBITDA margin.